Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
Type:
Grant
Filed:
January 29, 2018
Date of Patent:
October 29, 2019
Assignee:
Astute Medical, Inc.
Inventors:
Ravi A. Vijayendran, Srivatsa Venkatasubbarao
Abstract: The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.
Type:
Application
Filed:
June 6, 2017
Publication date:
October 3, 2019
Applicants:
ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
PAUL MCPHERSON, JAMES PATRICK KAMPF, JOHN A. KELLUM
Abstract: It is an object of the present invention to provide improved methods and compositions for manufacture and use of lateral flow test devices. In particular, the present invention provides a molding method which provides one or more features in the housing base configured to retain the test strip within the base. These features are provided as undercuts in the housing base. The test strip is configured as a bibulous lateral flow material disposed on a substantially non-compressible base layer, and the base layer is positioned within the undercut in order to retain the test strip in the housing base. Optionally, one or more features in the housing base which create the undercut are configured to engage the bibulous lateral flow material by compression and/or friction, thereby increasing the ability of the base to maintaining the test strip in its proper position within the device.
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
Type:
Application
Filed:
December 31, 2018
Publication date:
August 29, 2019
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: The invention provides methods for the treatment of subjects having or at risk of having kidney injuries using antibodies that specifically bind Metalloproteinase inhibitor 2 (TIMP-2). Specifically, the methods can be used for the treatment of a subject having chronic kidney disease (CKD), acute kidney injury (AKI), or a subject having an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, or acute renal failure (ARP).
Type:
Application
Filed:
October 27, 2017
Publication date:
August 29, 2019
Applicants:
ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Immumoglobulin A, Metalloproteinase inhibitor 4, and Thrombomodulin as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Application
Filed:
January 18, 2019
Publication date:
August 15, 2019
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of hyaluronic acid (HA) as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Application
Filed:
January 18, 2019
Publication date:
July 25, 2019
Applicants:
ASTUTE MEDICAL, INC., THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
JOSEPH ANDERBERG, JEFF GRAY, PAUL MCPHERSON, KEVIN NAKAMURA, JAMES PATRICK KAMPF, KAI SINGBARTL, JOHN A. KELLUM
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2-microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.
Type:
Grant
Filed:
November 5, 2010
Date of Patent:
June 18, 2019
Assignee:
Astute Medical, Inc.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.
Type:
Grant
Filed:
December 3, 2014
Date of Patent:
May 28, 2019
Assignees:
Astute Medical, Inc., University of Pittsburgh - of the Commonwealth System of Higher Education
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect Chitinase-3-like protein 1 as a predictive biomarker in renal injuries.
Type:
Application
Filed:
December 21, 2018
Publication date:
April 25, 2019
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect Chitinase-3-like protein 1 as a predictive biomarker in renal injuries.
Type:
Application
Filed:
May 16, 2018
Publication date:
September 6, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in appendicitis patients and in patients at risk for appendicitis. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.
Type:
Application
Filed:
June 17, 2016
Publication date:
August 9, 2018
Applicants:
ASTUTE MEDICAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Paul McPHERSON, James Patrick KAMPF, Thomas KWAN, Richard BACHUR, Hanno STEEN
Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
Type:
Application
Filed:
January 29, 2018
Publication date:
June 14, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Ravi A. VIJAYENDRAN, Srivatsa VENKATASUBBARAO
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Follistatin-related protein 3, Basigin, Cathepsin B, and Tenascin as diagnostic and prognostic bio-marker assays in renal injuries.
Type:
Application
Filed:
June 10, 2016
Publication date:
June 14, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph ANDERBERG, Paul McPHERSON, Jeff GRAY, Kevin NAKAMURA, James Patrick KAMPF, Thomas KWAN
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulinlike growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.
Type:
Application
Filed:
May 12, 2016
Publication date:
April 5, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph ANDERBERG, Paul MCPHERSON, Jeff GRAY, Kevin NAKAMURA, James Patrick KAMPF, Thomas KWAN
Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.
Type:
Application
Filed:
April 8, 2016
Publication date:
March 15, 2018
Applicants:
ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS TEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER
Inventors:
Paul McPherson, John A. Kellum, Jr., Alexander Zarbock
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Proheparin-binding EGF-like growth factor, Tenascin C, Angiopoietin-related protein 4, Fibroblast growth factor 19, Fibroblast growth factor 21, Heparin-binding growth factor 1, Angiopoietin-related protein 6, Proepiregulin, Probetacellulin, Amphiregulin, Angiogenin, Thrombospondin-2, and Collagen alpha-1(XVIII) chain as diagnostic and prognostic biomarkers in renal injuries.
Type:
Application
Filed:
November 20, 2017
Publication date:
March 8, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
Type:
Application
Filed:
November 20, 2017
Publication date:
March 8, 2018
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Ravi A. VIJAYENDRAN, Srivatsa VENKATASUBBARAO
Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
Type:
Grant
Filed:
August 7, 2014
Date of Patent:
January 30, 2018
Assignee:
ASTUTE MEDICAL, INC.
Inventors:
Ravi A. Vijayendran, Srivatsa Venkatasubbarao
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.
Type:
Application
Filed:
August 14, 2017
Publication date:
December 21, 2017
Applicant:
ASTUTE MEDICAL, INC.
Inventors:
Paul McPherson, Jeff Gray, James Patrick Kampf, Joseph Anderberg, Kevin Nakamura